CYTOKINETICS INC
Capricor Therapeutics shares rose over 60% after CEO Linda Marbán said the FDA is willing to review an amended deramiocel submission for Duchenne muscular dystrophy, with an Aug. 22 decision deadline. Cytokinetics sued Bristol Myers Squibb over patents tied to Myqorzo. Valneva gained after EMA accepted a Pfizer vaccine application. Other updates covered funding, licensing, and drug availability.
Cytokinetics (CYTK) reported Q2 2026 revenue of $28.6M, down from $66.8M in 2025 due to fewer Bayer milestone payments, with MYQORZO net product revenue of $25.3M. Cash and investments were $1.7B after a May offering. Operating expense guidance was raised to $860M-$890M; net loss was $198.8M. MYQORZO new-to-brand share exceeded 40% in June.
Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $76.76 ($0.58M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CYTK (CYTOKINETICS INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CYTK coverage spans insider activity, market movers and earnings.
In the last 30 days, CYTK insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($2.6M). The most active reporter was Blum Robert I, President & CEO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The lawsuit is a direct risk and potential upside catalyst for Myqorzo’s competitive position versus Camzyos, affecting sales and litigation overhang.
Launch traction for MYQORZO and a planned expansion into non-obstructive HCM are the core catalysts, offset by ongoing safety and cancellation risk.
The filing is a routine insider sale under a pre-arranged 10b5-1 plan, with limited direct fundamental signal.
New commercial traction for MYQORZO and positive Phase 3 topline for aficamten in nHCM are likely to re-rate near-term probability-weighted value, while the large cash raise funds expansion.
This is a routine, pre-arranged insider sale disclosure, not an earnings or guidance catalyst.
alphai scores every news story that mentions CYTK with an AI model for sentiment and relevance, and aggregates insider trades from CYTOKINETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Capricor Therapeutics shares rose over 60% after CEO Linda Marbán said the FDA is willing to review an amended deramiocel submission for Duchenne muscular dystrophy, with an Aug. 22 decision deadline. Cytokinetics sued Bristol Myers Squibb over patents tied to Myqorzo. Valneva gained after EMA accepted a Pfizer vaccine application. Other updates covered funding, licensing, and drug availability.
4 min readCytokinetics (CYTK) reported Q2 2026 revenue of $28.6M, down from $66.8M in 2025 due to fewer Bayer milestone payments, with MYQORZO net product revenue of $25.3M. Cash and investments were $1.7B after a May offering. Operating expense guidance was raised to $860M-$890M; net loss was $198.8M. MYQORZO new-to-brand share exceeded 40% in June.
10 min readBlum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $76.76 ($0.58M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
2 min readCYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup
6 min readCallos Andrew (EVP, Chief Commercial Officer) sold 14,000 shares of CYTOKINETICS INC (CYTK) at $79.88 ($1.12M total) on 2026-07-30 under a Rule 10b5-1 trading plan.
2 min readCytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).
4 min readCytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.
4 min readBlum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $80.87 ($0.61M total) on 2026-07-27 under a Rule 10b5-1 trading plan.
2 min readCytokinetics (CYTK) is commercializing MYQORZO (aficamten), approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The U.S. launch began in January 2026 and Europe is planned for Germany in Q2 2026. In 2025, revenue rose to $88.0M and net loss widened to $784.9M, while cash was about $1.22B.
6 min readBlum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $82.02 ($0.62M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
1 min read
